Hepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The liver is a preferred target organ for gene therapy not only for liver-specific diseases but also for disorders that require systemic delivery of a protein. Diseases that could benefit from hepatic gene transfer include hemophilia, metabolic disorders, lysosomal storage disorders, and others. For a successful delivery of the transgene and sustained expression, the protocol must avoid immune responses in order to be efficacious. A growing number of studies have demonstrated that liver-directed transfer can induce transgene product-specific immune tolerance. Tolerance obtained via this route requires optimal engineering of the vector to eliminate transgene expression in antigen presenting cells while restricting high levels of therapeutic expression to hepatocytes. Innate immune responses may prevent tolerance induction, cause toxicity, and have to be minimized. Discussed in our review is the crucial role of CD4(+)CD25(+) regulatory T cells in tolerance to the hepatocyte-derived gene product, the immunobiology of the liver and our current understanding of its tolerogenic properties, current and proposed research as to the mechanisms behind the liver's unique cellular environment, as well as development of the tools for tolerance induction such as advanced vector systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Limmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“LSEC are equipped to present antigen to both CD4+ and CD8+ T-cells, but the most common consequence of T cell priming is antigen-specific tolerance instead of immunity [19,25,26].”
BackgroundCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“Vector administration correlated with a CTL response against viral capsid proteins, which has been hypothesized to have resulted in the killing of hepatocytes harboring input capsid antigen, which may be cross-presented by MHC I to CD8+ T cells [60].”
BackgroundHepatic T cells and liver tolerance
Crispe, I. N. (2003) · Nature Reviews Immunology · doi:10.1038/nri981 · Cited by 661 · cited 1×
“LSEC are equipped to present antigen to both CD4+ and CD8+ T-cells, but the most common consequence of T cell priming is antigen-specific tolerance instead of immunity [19,25,26].”
BackgroundBrown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 1×
“This has been attributed to low innate immunity to AAV and to the inefficiency of the virus to infect DC or macrophages [54].”
BackgroundInduction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 3×
“This unresponsiveness cannot be explained by a shift in cytokine secretion patterns or in isotype switch for antibody production, ruling out an immune deviation mechanism [76].”
BackgroundSelf-citationSnyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394
Resident human hepatitis lymphocytes are phenotypically different from circulating lymphocytes
Norris, S., Collins, C., Doherty, D. G., Smith, F., McEntee, G., Traynor, O., Nolan, N., Hegarty, J., & O'Farrelly, C. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80206-7 · Cited by 374 · cited 1×
“In mice, the liver contains a high percentage of activated cells of both subsets [28].”
BackgroundWarren, A., Le Couteur, D. G., Fraser, R., Bowen, D. G., McCaughan, G. W., & Bertolino, P. (2006) · Hepatology · doi:10.1002/hep.21378 · Cited by 347
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationImmune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Bowen, D. G., Zen, M., Holz, L., Davis, T., McCaughan, G. W., & Bertolino, P. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21593 · Cited by 316
KNOLLE, P., SCHMITT, E., JIN, S., GERMANN, T., DUCHMANN, R., HEGENBARTH, S., GERKEN, G., & LOHSE, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70508-1 · Cited by 298 · cited 2×
“Depending on how the antigen arrives at the liver, whether by systemic means or via the portal circulation, there can be marked differences in final response [25,71].”
BackgroundNiemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., & Lothrop, C. D. (2009) · Blood · doi:10.1182/blood-2008-10-181479 · Cited by 276
Self-citationMingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254 · cited 1×
“IX in non-human primates suggest that the hepatic tolerance phenomenon can also be attributed to species other than mice, including large animal models [55,57,82,83].”
BackgroundA microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252
Cao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C., & Herzog, R. W. (2007) · Blood · doi:10.1182/blood-2007-02-073304 · Cited by 220
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Herzog, R. W., Mount, J. D., Arruda, V. R., High, K. A., & Lothrop, C. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0442 · Cited by 176
Self-citationInduction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer
Dobrzynski, E., Mingozzi, F., Liu, Y.-L., Bendo, E., Cao, O., Wang, L., & Herzog, R. W. (2004) · Blood · doi:10.1182/blood-2004-03-0847 · Cited by 135
Self-citationPeripheral deletion of autoreactive CD8+ T cells in transgenic mice expressing H‐2Kb in the liver
Bertolino, P., Heath, W. R., Hardy, C. L., Morahan, G., & Miller, J. F. A. P. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250721 · Cited by 133 · cited 1×
“Additionally, it has been suggested that hepatocytes are capable of activating naïve CD8+ T-cells without any prior lymph node priming [6,13].”
BackgroundDobrzynski, E., Fitzgerald, J. C., Cao, O., Mingozzi, F., Wang, L., & Herzog, R. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508685103 · Cited by 105
Self-citation
Cited by
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
Self-citationA dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3469 · Cited by 556
“However, systemic delivery of AAV in a newborn helps mitigate potential immunologic adverse events for several reasons 26–28 .”
Wan, T., Zhong, J., Pan, Q., Zhou, T., Ping, Y., & Liu, X. (2022) · Science Advances · doi:10.1126/sciadv.abp9435 · Cited by 299
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Self-citationInnate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178
Self-citation
Metadata
- Authors
- LoDuca, P., Hoffman, B., & Herzog, R.
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-04-01
- Volume
- 9
- Issue
- 2
- Pages
- 104-114
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W2159050641
- Cited by
- 114
- References
- 25
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.